Medscape:血压治疗指标不一定适用于感染性休克

2014-04-25 佚名 dxy

在医学院里学习了自动调节曲线确定血压(BP)和器官灌注的关系。血压是不固定的,其与阻力有关,而阻力与血管的直径有关。 在一定范围内的血压,器官灌注量是足够的。而该范围随器官和病人的因素而变化,例如年龄和合并症。当血管收缩使血压升高超过该范围,血流的阻力增加(由于直径的减小),器官灌注量无法保持。同样的,当血管舒张使血压下降超过该范围时,血流的驱动压力下降,器官的灌注量再次受损。 重症医学会的《

在医学院里学习了自动调节曲线确定血压(BP)和器官灌注的关系。血压是不固定的,其与阻力有关,而阻力与血管的直径有关。

在一定范围内的血压,器官灌注量是足够的。而该范围随器官和病人的因素而变化,例如年龄和合并症。当血管收缩使血压升高超过该范围,血流的阻力增加(由于直径的减小),器官灌注量无法保持。同样的,当血管舒张使血压下降超过该范围时,血流的驱动压力下降,器官的灌注量再次受损。

重症医学会的《拯救脓毒症患者》指南被称为败血症治疗的圣经。指南中建议复苏过程的目标血压范围为平均动脉压大于65mmHg。

该指南承认对所有患者和所有器官都通用的目标是不存在的。个体化的目标是理想状态,但除了器官低灌注时的广泛或组织特异性标志物外,没有其他可以指导临床治疗的内容。

感染性休克患者平均动脉压(MAP)目标比较

2014年3月18日,NEJM上在线发表了一项比较感染性休克患者目标MAP的随机对照试验。MAP为65-70mmHg为低血压组,80-85mmHg为高血压组。

有慢性高血压病史患者被分入一个亚组进行单独分析。主要的终点事件为28天时的死亡率。各组患者无显著性差异。但有几个重要的发现。

首先,研究人员花费大量的时间使两组患者达到其指定的目标血压范围。其次,高目标组的患者可能经历房颤,并获得更多的总儿茶酚胺。最后,有慢性高血压的高目标组患者不大可能发生血浆血清肌酐翻倍,不太可能需要肾脏替代治疗。

该研究存在的不足

从上述研究结果中学到了什么?即使是事先设计的,医生并没有让患者的MAP下降至65mmHg。这可能是由于根深蒂固的思维,或它可能只反映血压不稳,难以维持在5mmHg范围内。临床上房颤和肾脏替代治疗都是应该力求避免的重要终点事件。

如果作者能提供儿茶酚胺剂量和心房颤动的数据,那就更好了。特定剂量时心率是否增加?加入肾上腺素还是去甲肾上腺素时更常见?如果知道这些问题的答案,也许能够将有高血压病史患者的MAP定在80mmHg,同时尽量减少诱发房颤的风险。

原始链接

Aaron B. Holley, MD.Lower Blood Pressure in Sepsis?April 16, 2014

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897949, encodeId=727d189e9497f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Nov 10 02:40:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725596, encodeId=9e881e255969a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 28 22:40:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655327, encodeId=a50c165532e8d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 01 20:40:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350948, encodeId=c7aa13509488d, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458549, encodeId=868a1458549cd, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606171, encodeId=025316061e140, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-11-10 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897949, encodeId=727d189e9497f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Nov 10 02:40:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725596, encodeId=9e881e255969a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 28 22:40:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655327, encodeId=a50c165532e8d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 01 20:40:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350948, encodeId=c7aa13509488d, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458549, encodeId=868a1458549cd, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606171, encodeId=025316061e140, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2015-02-28 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897949, encodeId=727d189e9497f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Nov 10 02:40:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725596, encodeId=9e881e255969a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 28 22:40:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655327, encodeId=a50c165532e8d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 01 20:40:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350948, encodeId=c7aa13509488d, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458549, encodeId=868a1458549cd, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606171, encodeId=025316061e140, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897949, encodeId=727d189e9497f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Nov 10 02:40:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725596, encodeId=9e881e255969a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 28 22:40:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655327, encodeId=a50c165532e8d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 01 20:40:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350948, encodeId=c7aa13509488d, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458549, encodeId=868a1458549cd, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606171, encodeId=025316061e140, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
    2014-04-27 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897949, encodeId=727d189e9497f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Nov 10 02:40:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725596, encodeId=9e881e255969a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 28 22:40:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655327, encodeId=a50c165532e8d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 01 20:40:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350948, encodeId=c7aa13509488d, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458549, encodeId=868a1458549cd, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606171, encodeId=025316061e140, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1897949, encodeId=727d189e9497f, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Nov 10 02:40:00 CST 2014, time=2014-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725596, encodeId=9e881e255969a, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Feb 28 22:40:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655327, encodeId=a50c165532e8d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 01 20:40:00 CST 2014, time=2014-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350948, encodeId=c7aa13509488d, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458549, encodeId=868a1458549cd, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606171, encodeId=025316061e140, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 27 05:40:00 CST 2014, time=2014-04-27, status=1, ipAttribution=)]

相关资讯

CJASN:控制尿蛋白和血压是防止IgA肾病进展的关键

北京大学第一医院肾内科吕继成教授等开展的一项前瞻性研究表明,对于我国IgA肾病患者,有效控制尿蛋白和血压是预防估算肾小球滤过率(eGFR)下降和终末期肾病的关键措施。 研究者指出,目前IgA肾病的治疗措施主要包括肾素-血管紧张素系统阻滞剂和激素。在该研究中,703例IgA肾病患者至少接受 12 个月随访,平均随访 45个月。受试者的eGFR年下降速度为3.12 m

颅内外动脉狭窄患者如何管理血压?

“十一五”期间,一项来自于20多家医院的流行病学研究,对2864例缺血性卒中和短暂性脑缺血发作患者行头颅磁共振血管成像检查,发现46.6%患者合并颅内动脉狭窄(狭窄率>50%),颅内狭窄并存患者占9%,单纯颈动脉狭窄患者占4%。 首都医科大学附属北京天坛医院王拥军教授介绍,该流行病学研究同时发现另外一个现象,单纯颅内动脉硬化狭窄并不会引起卒中复发增加,如果叠

NEJM:血压治疗指标差异或不影响感染性休克死亡率

根据拯救败血症患者运动(SSC)指南推荐,在临床救治感染性休克患者的早期复苏阶段,治疗者应保证患者的平均动脉压至少达到65mmHg。但是,实际的情况是,我们并不清楚指南推荐的血压治疗指标与较高血压治疗指标在临床治疗效果上的差异。法国研究者Asfar教授就上述问题开展了研究,其研究成果发表于3月18日的NEJM杂志。研究者进行了一个多中心开放性试验,776名患者入组,均换感染性休克并接受了复苏治疗。

Neurology:正常高值血压也增卒中风险

中国广州南方医科大学附属南方医院许顶立教授牵头的一项荟萃分析表明,血压高于最佳值但低于高血压诊断阈值的人群(正常高值血压)卒中形成风险也增加。论文发表于《神经病学》(Neurology)。 研究者检索了相关数据库,并纳入了在高血压前期人群,以及在血压高于最佳值(120/80 mmHg)但低于高血压诊断阈值(140/90 mmHg)人群中评估卒中形成风险的研究。 结果显示,共有包括760

正常高值血压:一个需要特别关注的血压阶段

2003年的美国高血压指南(JNC-7)将血压分为:正常血压、正常高值血压及高血压[1]。目前对于高血压的诊疗已有广泛共识[2,3],然而对于正常高值血压的诊疗存在较大争议,主要包括:是否应该存在此概念,以及药物干预是否必要等[4]。我们对成都地区自然人群进行了研究,旨在探讨正常高值血压概念存在的必要性以及是否应当早期进行干预等。1 资料与方法1.1 一般资料  1992年,我们根据世界卫生组

Stroke:持续性血压控制改善缺血性脑卒中预后

缺血性脑卒中后需进行长期血压控制,可是却少有研究去证实血压控制与缺血性脑卒中预后的关系,持续性血压控制能否减少缺血性脑卒中后血管意外的发生,最近美国Rancho Los国家康复中心Towfighi等研究者通过一系列事后分析研究表明持续性血压控制能减少缺血性卒中后血管意外的发生,这篇文章于3月27日发表在Stroke上。【原文下载】该项调查是随机、双盲、可控制的事后调查分析,在1996年9月到200